1. Home
  2. ICCC vs TURN Comparison

ICCC vs TURN Comparison

Compare ICCC & TURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • TURN
  • Stock Information
  • Founded
  • ICCC 1982
  • TURN 1981
  • Country
  • ICCC United States
  • TURN United States
  • Employees
  • ICCC N/A
  • TURN N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • TURN Finance/Investors Services
  • Sector
  • ICCC Health Care
  • TURN Finance
  • Exchange
  • ICCC Nasdaq
  • TURN Nasdaq
  • Market Cap
  • ICCC 35.4M
  • TURN 37.1M
  • IPO Year
  • ICCC 1987
  • TURN N/A
  • Fundamental
  • Price
  • ICCC $4.16
  • TURN $3.58
  • Analyst Decision
  • ICCC
  • TURN
  • Analyst Count
  • ICCC 0
  • TURN 0
  • Target Price
  • ICCC N/A
  • TURN N/A
  • AVG Volume (30 Days)
  • ICCC 6.0K
  • TURN 12.6K
  • Earning Date
  • ICCC 08-08-2024
  • TURN 08-12-2024
  • Dividend Yield
  • ICCC N/A
  • TURN N/A
  • EPS Growth
  • ICCC N/A
  • TURN 108.06
  • EPS
  • ICCC N/A
  • TURN 1.29
  • Revenue
  • ICCC $21,282,719.00
  • TURN N/A
  • Revenue This Year
  • ICCC N/A
  • TURN N/A
  • Revenue Next Year
  • ICCC N/A
  • TURN N/A
  • P/E Ratio
  • ICCC N/A
  • TURN $2.78
  • Revenue Growth
  • ICCC 32.89
  • TURN N/A
  • 52 Week Low
  • ICCC $4.05
  • TURN $3.53
  • 52 Week High
  • ICCC $5.75
  • TURN $4.97
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 42.25
  • TURN 36.82
  • Support Level
  • ICCC $4.10
  • TURN $3.53
  • Resistance Level
  • ICCC $4.29
  • TURN $3.69
  • Average True Range (ATR)
  • ICCC 0.11
  • TURN 0.06
  • MACD
  • ICCC -0.00
  • TURN -0.00
  • Stochastic Oscillator
  • ICCC 13.04
  • TURN 19.23

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About TURN 180 Degree Capital Corp.

180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.

Share on Social Networks: